Quick Answer
Pharming Group N.V. reported R&D Expense of $83.15 million for fiscal year 2024.
Pharming Group N.V. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $83.15M | +20.7% |
| 2023 | $68.91M | +31.2% |
| 2022 | $52.53M | -25.3% |
| 2021 | $70.37M | +82.7% |
| 2020 | $38.52M | +35.8% |
| 2019 | $28.37M | -1.8% |
| 2018 | $28.88M | — |
- Pharming Group N.V. showed an increase of +20.7% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2024 period, Pharming Group N.V.’s r&d expense has grown by 187.9% (from $28.88 million to $83.15 million).
- The most recent figure is from Pharming Group N.V.’s fiscal year 2024 report (Form 20-F), filed with the SEC on April 3, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: